- Home
- REX vs IMTX Comparison
REX vs IMTX Comparison
Compare REX & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | IMTX |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | REX | IMTX |
|---|---|---|
| Price | $43.94 | $9.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 159.3K | ★ 527.9K |
| Earning Date | 05-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $650,487,000.00 | N/A |
| Revenue This Year | $19.45 | N/A |
| Revenue Next Year | N/A | $25.91 |
| P/E Ratio | $76.79 | ★ N/A |
| Revenue Growth | ★ 1.24 | N/A |
| 52 Week Low | $30.02 | $5.05 |
| 52 Week High | $64.95 | $12.41 |
Technical Indicators
Market Signals| Indicator | REX | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.58 | 37.00 |
| Support Level | $31.24 | $9.05 |
| Resistance Level | $49.85 | $10.64 |
| Average True Range (ATR) | 2.21 | 0.59 |
| MACD | -0.63 | -0.20 |
| Stochastic Oscillator | 15.22 | 19.11 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company that engages in investments in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include Ethanol, dried distillers grains, modified distillers grains, Distillers corn oil, Modified distillers grains, and Other.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.